Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18F-PSMA) PET / CT in the Management of Patients With Prostate Cancer.

Prostate Cancer Clinical Trial

— F-PSMA  

Official title:

Experimental Study to Evaluate the Impact of 18F-PSMA PET / CT in the Management of Patients With Prostate Cancer.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04775602
• Other study ID #: IRST185.07
• Secondary ID: 2019-002000-41
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: May 2021
• Est. completion date: August 2022

Study information

• Verified date: February 2021
• Source: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
• Contact: Federica Matteucci, MD
• Phone: +390543739249
• Email: federica.matteucci[@]irest.emr.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Single-center, prospective, open-label, not randomized, diagnostic phase II trial in the management of patients with prostate cancer.

Description:

Single-center, prospective, open-label, not randomized, diagnostic phase II trial in the management of patients with prostate cancer. The aim of this study is to evaluate the additional diagnostic role of 18F- PSMA PET /CT (sensitivity) in patients with prostate cancer with biochemical relapse compared to other diagnostic methods routinely used. The primary objective is to evaluate the sensitivity of 18F-PSMA PET/CT defined as the ratio between the number of 18F-PSMA PET/CT positive patients and the number of prostate cancer patients with biochemical relapse and negative standard imaging.Patients enrolled in the study would benefit from a more accurate but above all earlier diagnosis of disease recurrence sites, thus being able to undergo targeted therapies, with a clear impact on the clinical management of the disease.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 500
• Est. completion date: August 2022
• Est. primary completion date: August 2022
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients must have histologically or cytologically confirmed prostate cancer

2. Male, aged >18 years on the day of signing and dating the informed consent form.

3. Previous radical treatment for prostate cancer (radiotherapy or surgery)

4. Negativity of all the other traditional morphological and functional imaging or doubtful imaging of 18F-FMC PET/CT

5. Patients with PSA progression defined as PSA = 0.2 ng/mL and PSA rising defined as 2 subsequent values showing PSA increase at least 1 week apart.

6. Male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter

7. Participant is willing and able to give informed consent for participation in the study.

Exclusion Criteria:

1. Hormonotherapy in the last 6 months

2. No radiotherapy in the last 6 months.

3. Participation in another clinical trial with any investigational agents within 30 days prior to prior informed consent date

4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Study Agent.

5. Medical or psychological conditions that would not permit the subject to sign the informed consent

Related Conditions & MeSH terms

• 18F-PSMA
• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• 18F-PSMA
18F-PSMA will be injected intravenously at a dosage of 200-250 megabecquerel (MBq) prior to perform Image acquisition (Topogram, CT, PET)

Locations

Country	Name	City	State
Italy	Irst Irccs	Meldola	FC

Sponsors (1)

Lead Sponsor	Collaborator
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnostic role of 18F- PSMA PET /CT (sensitivity)	Sensitivity of 18F-PSMA PET/CT will be calculated as the ratio between the number of 18F- PSMA PET/CT positive patients and number of patients with radically treated prostate cancer with biochemical relapse and negativity of traditional morphological imaging.	Up to 30 months
Secondary	Sensitivity for different PSA values (ranges)	Sensitivity of 18F-PSMA PET/CT will be stratified respect to different ranges of Prostate-Specific Antigen (PSA) values.	Up to 30 months
Secondary	Sensitivity for different lesion sites	Sensitivity of 18F-PSMA PET/CT will be stratified respect to different sites of lesion.	Up to 30 months
Secondary	predictive role of 18F-PSMA PET/CT on disease status according to standard imaging and PSA evaluation.	To evaluate the predictive role of 18F-PSMA PET/CT on disease status, for patients that will start an anticancer treatment. It will be performed the receiver operating characteristic (ROC) curves generated by plotting sensitivity versus 1-specificity The best cut-off value for distinguishing between positive and negative 18F- PSMA PET/CT findings will be determined using Youden's index.	Up to 30 months
Secondary	evaluation of the concordance between 18F-PSMA PET/CT and other methods	To evaluate the concordance between 18F-PSMA PET/CT and PET/CT or the others standard methods, for patients without any treatment, it will be performed by Cohen's kappa coefficient	Up to 30 months
Secondary	18F-PSMA Safety: treated patients undergoing grade 1 to 4 adverse event	Number and percentage of treated patients undergoing grade 1 to 4 adverse events will be tabulated according to CTCAE version 5.0.	Up to 30 months